Pharma Mar, S.A. (BME:PHM)
Spain · Delayed Price · Currency is EUR 78.65
+0.95 (1.22%)
Aug 7, 2026, 2:50 PM CET
Pharma Mar Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 221.39 | 349.96 | 158.15 | 359.47 | 229.83 | |
Revenue Growth | -36.74% | 121.28% | -56.00% | 56.41% | -14.87% |
Cost of Revenue | 12.26 | 10.99 | 9.61 | 12.21 | 16.44 |
Gross Profit | 209.13 | 338.97 | 148.54 | 347.26 | 213.39 |
Selling, General & Admin | 73.66 | 47.32 | 54.59 | 38.06 | 39.74 |
Depreciation & Amortization Expenses | - | 3.6 | - | 3 | - |
Research & Development | 95.19 | - | 99.3 | - | 72.17 |
Other Operating Expenses | -20.44 | 91.11 | -0.98 | 64.57 | 9.23 |
Total Operating Expenses | 148.42 | 142.03 | 152.91 | 105.64 | 121.14 |
Operating Income | 60.72 | 21.97 | -3.83 | 61.88 | 92.45 |
Interest Income | - | 6.84 | - | 1.59 | - |
Interest Expense | -6.51 | -2.15 | -9.43 | -3.63 | -7.68 |
Other Non-Operating Income (Expense) | -1.06 | -3.08 | 0.2 | -5.41 | 2.68 |
Total Non-Operating Income (Expense) | -7.57 | 1.61 | -9.22 | -7.45 | -5 |
Pretax Income | 59.65 | 23.58 | -3.62 | 58.16 | 95.13 |
Provision for Income Taxes | -15.34 | -16.65 | -4.76 | -0.8 | 2.27 |
Net Income | 74.99 | 40.23 | 1.14 | 58.95 | 92.86 |
Net Income to Common | 74.99 | 40.23 | 1.14 | 58.95 | 92.86 |
Net Income Growth | 86.42% | 3437.82% | -98.07% | -36.51% | -32.35% |
Shares Outstanding (Basic) | 17 | 18 | 18 | 18 | 18 |
Shares Outstanding (Diluted) | 17 | 18 | 18 | 18 | 18 |
Shares Change | -0.62% | -1.98% | -0.81% | -0.12% | -1.31% |
EPS (Basic) | 4.30 | 1.49 | 0.06 | 2.73 | 5.14 |
EPS (Diluted) | 4.30 | 1.49 | 0.06 | 2.73 | 5.13 |
EPS Growth | 188.59% | 2383.33% | -97.80% | -46.78% | -31.51% |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 46.67 | -8.99 | -10.1 | 29.47 | 31.92 |
Free Cash Flow Growth | - | - | - | -7.68% | -88.43% |
Free Cash Flow Per Share | 2.67 | -0.51 | -0.56 | 1.63 | 1.76 |
Dividends Per Share | 1.000 | 0.800 | 0.650 | 0.650 | 0.650 |
Dividend Growth | 25.00% | 23.08% | 0% | 0% | 8.33% |
Gross Margin | 94.46% | 96.86% | 93.92% | 96.60% | 92.85% |
Operating Margin | 27.42% | 6.28% | -2.42% | 17.22% | 40.22% |
Profit Margin | 33.87% | 11.49% | 0.72% | 16.40% | 40.40% |
FCF Margin | 21.08% | -2.57% | -6.38% | 8.20% | 13.89% |
EBITDA | 68.74 | 28.74 | -0.52 | 67.78 | 95.13 |
EBITDA Margin | 31.05% | 8.21% | -0.33% | 18.86% | 41.39% |
EBIT | 60.72 | 21.97 | -3.83 | 61.88 | 92.45 |
EBIT Margin | 27.42% | 6.28% | -2.42% | 17.22% | 40.22% |
Effective Tax Rate | -25.71% | -70.62% | 131.38% | -1.37% | 2.39% |